UNSPSC 51384624: Bendazac sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4SW243Q44Z, chemically known as sodium, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate but more generally known as bendazac sodium, which bears US NIH Compound Identifier 31020. European Medicines Agency schedules Bendazac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00698MIG.

Most nations, for tariff and trade purposes, schedule bendazac sodium under HS 29339990. As of Q4 2014, BENDAZAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2C3CCCCC3C(N2)OCC(=O)[O-].[NA+].

UNSPSC 51384624 Bendazac sodium is a Commodity code representing a specific pharmaceutical product, but the recent state and local procurement activity tagged under it shows a significant mismatch with the code's nominal scope. The single available recent opportunity, Seminole County, Florida's IFB 60459723LAS posted June 30, 2026, solicits naloxone and drug deactivation systems — neither of which is bendazac sodium. Bendazac sodium is a nonsteroidal anti-inflammatory drug used primarily for ocular conditions; naloxone is an opioid antagonist used in overdose response, and drug deactivation systems are disposal or neutralization equipment. This procurement is responsive to community health and public safety initiatives rather than pharmaceutical inventory for clinical use, and the tagging appears to reflect a data-entry or classification error rather than genuine purchasing activity under the bendazac code.

Seminole County's solicitation calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building in Sanford, Florida. The IFB has a two-year initial term with an optional one-year renewal, and vendors must submit bids electronically with all shipping and delivery costs included; the response deadline was July 26, 2023. The procurement requires E-Verify compliance, drug-free workplace certification, and standard commercial insurance, with potential FEMA funding introducing additional federal environmental compliance obligations. No explicit set-aside designations are noted. The code shows little relevant recent activity aligned with bendazac sodium procurement at the state and local level — the single identified opportunity involves a different product class entirely, making this code a skip for firms pursuing pharmaceutical supply contracts in traditional clinical or pharmacy settings.